Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group (Q33885648)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

phase III clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

8

object named as

P Emery

0 references

E. William St. Clair

2

object named as

E W St Clair

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

R Maini

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

F Breedveld

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

D Furst

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

J Kalden

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

M Weisman

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

J Smolen

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

G Harriman

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

M Feldmann

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

P Lipsky

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 December 1999

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

354

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

9194

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1932-1939

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2905246-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(99)05246-0

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33885648&oldid=1647844468"